Kidney disease is one of the diabetes complications I want my patients to understand early, because kidney damage can begin long before you notice swelling, pain, or changes in urination. A person may feel completely well while important kidney tests are already beginning to change.
The good news is that diabetic kidney disease can often be detected early with simple blood and urine tests, and modern treatment can substantially slow its progression. The two numbers you will hear most often are UACR, which checks for albumin leaking into the urine, and eGFR, which estimates how well the kidneys are filtering your blood.
On this page, I will explain what these tests mean, who should be screened, which symptoms deserve attention, and how glucose, blood pressure, medicines, nutrition, and lifestyle can help protect your kidneys. For a broader overview of problems diabetes may cause over time, see our guide to diabetes complications, warning signs, and prevention.
Diabetic nephropathy, also called diabetic kidney disease (DKD), is chronic kidney damage associated with diabetes. It usually develops gradually and often causes no symptoms in its early stages.
The two most important routine tests are the urine albumin-to-creatinine ratio (UACR), which looks for albumin leaking into the urine, and the estimated glomerular filtration rate (eGFR), which estimates kidney filtering function.
Protecting the kidneys involves more than lowering blood sugar. Modern care also addresses blood pressure, albuminuria, cardiovascular risk, smoking, weight, and kidney-protective medicines when they are appropriate for the individual patient.
Diabetic nephropathy is an older but still commonly used term for diabetic kidney disease. Diabetes can damage the kidneys over time through prolonged high glucose exposure, increased pressure within the kidney's filtering units, vascular injury, inflammation, and associated high blood pressure.
Kidney disease does not follow exactly the same timeline in every patient. In type 1 diabetes, diabetic kidney disease usually develops only after several years and is uncommon during the first five years. In type 2 diabetes, kidney disease may already be present when diabetes is first diagnosed because type 2 diabetes can remain undetected for years.
It is also important not to assume that every person with diabetes and chronic kidney disease has kidney damage caused entirely by diabetes. Other kidney disorders can occur at the same time. Doctors therefore interpret UACR, eGFR, urine findings, blood pressure, diabetes duration, retinal disease, medications, and the overall clinical picture together.
Kidney disease is part of the wider group of long-term complications associated with diabetes, which can also affect the eyes, nerves, feet, heart, and blood vessels.
When I discuss kidney disease with my patients, I emphasize one point: do not wait for swelling or fatigue before checking your kidneys. Early diabetic kidney disease is usually silent. You can feel completely well while albumin is already increasing in the urine or eGFR is beginning to fall.
Each kidney contains microscopic filtering structures called glomeruli. Under normal conditions, these filters remove waste and excess water from the blood while keeping important proteins such as albumin inside the bloodstream.
Long-term diabetes can place stress on this delicate filtration system through several related mechanisms:
Over time, albumin may begin leaking into the urine and structural changes may develop in the kidney filters. As functioning kidney tissue is lost, eGFR can gradually decline.
Because long-term glucose exposure is part of this process, keeping blood sugar within an individualized target remains important. Our normal blood sugar level chart explains how fasting, before-meal, after-meal, and A1C values are interpreted differently.
Because early kidney disease often has no obvious symptoms, routine screening is much more useful than waiting until you feel unwell.
Current diabetes guidance recommends checking UACR and eGFR at least once each year in:
Once chronic kidney disease is present, UACR and eGFR are generally checked more often, with the frequency depending on kidney stage, progression risk, treatment, and other medical factors.
Kidney screening is different from routine glucose monitoring. A glucose meter tells you what your blood sugar is doing at a particular moment, while HbA1c reflects longer-term glucose exposure. UACR and eGFR tell your healthcare team something different: whether kidney damage is present and how well your kidneys are functioning.
Patients sometimes focus only on blood creatinine, but doctors obtain a much clearer picture by looking at both urine albumin and estimated kidney filtration. UACR and eGFR provide complementary information and should usually be interpreted together.
UACR measures how much albumin is present in the urine relative to creatinine. Healthy kidneys normally keep most albumin in the bloodstream. Increasing albumin leakage can therefore be an early sign that the kidney filtration barrier is being damaged.
| UACR | Category | Meaning |
|---|---|---|
| <30 mg/g | A1 | Normal to mildly increased |
| 30–299 mg/g | A2 | Moderately increased albuminuria |
| ≥300 mg/g | A3 | Severely increased albuminuria |
One abnormal UACR does not automatically establish persistent kidney disease. Exercise, fever, infection, heart failure, menstruation, marked hyperglycemia, and markedly elevated blood pressure can temporarily increase urinary albumin.
Because albumin excretion varies naturally, doctors generally confirm persistent moderately or severely increased albuminuria with repeated testing. In many cases, two of three specimens collected over approximately 3–6 months should be abnormal before persistent albuminuria is confirmed.
eGFR estimates how effectively your kidneys are filtering blood. It is calculated from blood test information and is more useful for kidney assessment than looking at serum creatinine alone.
| eGFR (mL/min/1.73 m²) | Stage | General description |
|---|---|---|
| ≥90 | G1 | Normal/high; CKD requires another marker of kidney damage |
| 60–89 | G2 | Mildly reduced; CKD requires another marker of kidney damage |
| 45–59 | G3a | Mild-to-moderately reduced |
| 30–44 | G3b | Moderately-to-severely reduced |
| 15–29 | G4 | Severely reduced |
| <15 | G5 | Kidney failure |
A persistently reduced eGFR below 60 mL/min/1.73 m² may indicate chronic kidney disease even when UACR is normal. Conversely, a person may have significant albuminuria while eGFR remains relatively preserved.
This is why doctors use both UACR and eGFR instead of relying on a single kidney number. If you are trying to understand your diabetes numbers more generally, our blood glucose readings guide explains how glucose results fit into the overall diabetes picture.
Early diabetic kidney disease usually causes no symptoms. This is one of the most important messages on this page. Waiting until something feels wrong can mean missing the stage when kidney disease is easiest to identify and address.
As chronic kidney disease becomes more advanced, possible symptoms can include:
These symptoms are not specific to diabetic kidney disease and may have other causes. Hiccups, headache, nausea, or facial swelling alone are also not reliable early diagnostic signs.
This is why regular complication screening matters even when you feel well. Our diabetes complications guide explains other conditions that can also begin with few or no symptoms.
In most patients, diabetic kidney disease is diagnosed clinically rather than through an invasive procedure. Doctors look for a persistent pattern of albuminuria and/or reduced eGFR together with diabetes history, blood pressure, retinal findings, urine results, medication history, and evidence for or against another kidney disorder.
A kidney biopsy is not routinely required. A nephrologist may consider additional investigation or biopsy when the pattern is unusual.
Examples that may suggest another kidney disease include:
Kidney protection has changed substantially over the years. Treatment is no longer based on glucose control alone. The strongest approach combines individualized glucose management, blood-pressure control, reduction of albuminuria, cardiovascular-risk reduction, lifestyle treatment, and kidney-protective medication when appropriate.
Good glucose management reduces the risk of developing kidney complications and can help slow progression. For many nonpregnant adults, an A1C around 7% is a common starting goal, but the safest target must be individualized.
Advanced CKD can increase hypoglycemia risk, and A1C may become less reliable in certain advanced kidney conditions. Our guide to HbA1c and average blood glucose explains why the best A1C target is not identical for every patient.
Blood pressure is one of the major modifiable drivers of kidney and cardiovascular risk. Current ADA guidance generally recommends an on-treatment blood-pressure goal of below 130/80 mmHg when it can be achieved safely.
Your personal target may need adjustment if you experience dizziness, falls, frailty, medication side effects, or other conditions that affect how aggressively blood pressure can be lowered.
In nonpregnant people with diabetes, hypertension, and albuminuria, an ACE inhibitor or angiotensin receptor blocker (ARB) is an important kidney-protective treatment.
These medicines are particularly strongly recommended when UACR is at least 300 mg/g and/or eGFR is below 60 mL/min/1.73 m². Treatment is generally adjusted toward the highest tolerated dose while kidney function, potassium, and blood pressure are monitored.
ACE inhibitors and ARBs should not routinely be combined, and they are not recommended solely to prevent CKD when blood pressure, UACR, and eGFR are all normal.
For people with type 2 diabetes and chronic kidney disease, an SGLT2 inhibitor with proven kidney benefit is recommended when eGFR is at least 20 mL/min/1.73 m², unless there is a contraindication.
These medicines can reduce progression of kidney disease and lower cardiovascular and heart-failure risk, with benefits that are not explained only by their effect on blood glucose.
GLP-1 receptor agonists with demonstrated cardiovascular and kidney benefit may also be recommended for people with type 2 diabetes and CKD. The best choice depends on kidney function, cardiovascular history, weight goals, glucose needs, tolerability, and other medications.
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist that can reduce kidney-disease progression and cardiovascular events in selected people with type 2 diabetes, CKD, and albuminuria.
Current guidance recommends an effective nonsteroidal MRA in appropriate albuminuric CKD when eGFR is at least 25 mL/min/1.73 m². Potassium and kidney function must be monitored.
These drug classes work differently and are not interchangeable. If you would like a broader overview before discussing your treatment with your doctor, see our guide to diabetes medications, benefits, and side effects.
ACE inhibitors, ARBs, SGLT2 inhibitors, finerenone, insulin, metformin, GLP-1 medicines, and diuretics require individualized prescribing. Kidney function, potassium, hydration, blood pressure, pregnancy status, illness, and other medicines can all change what is safe for you.
If you are concerned about interactions or adverse effects, our diabetes drug safety and side-effects guide can help you prepare questions for your healthcare professional.
There is no single diet that is correct for every person with diabetic kidney disease. Nutrition needs change according to CKD stage, blood pressure, potassium, phosphorus, albuminuria, weight, diabetes treatment, and whether dialysis is required.
General principles may include:
If your kidney function is still normal or only mildly reduced, many principles of a balanced diabetes eating pattern may continue to apply. However, protein, sodium, potassium, phosphorus, and fluid needs can change as CKD progresses. Our diabetes diet guide provides general meal-planning advice, which should be individualized with a renal dietitian when kidney disease is present.
Medication is only one part of kidney protection. Everyday habits and management of other cardiovascular risk factors also matter.
Kidney disease is best followed by looking at trends over time, not by judging one isolated laboratory result. Your healthcare professional may follow UACR, eGFR, creatinine, potassium, blood pressure, A1C or other glucose measures, body weight, and fluid status.
In people with UACR of at least 300 mg/g, current diabetes guidance recommends aiming for a substantial reduction in urinary albumin, generally 30% or more when possible, because falling albuminuria can indicate improved kidney-risk control.
Do not be alarmed by every small variation in eGFR or UACR. Trends, repeat testing, medication changes, hydration, illness, and the complete clinical picture are more informative than one value alone.
Many people with early diabetic kidney disease can initially be managed by their diabetes or primary-care team. A kidney specialist becomes increasingly important when disease is advanced, progressing quickly, difficult to manage, or does not follow the expected pattern of diabetic kidney disease.
Referral to a nephrologist should be considered when:
If you have diabetes, especially if kidney results have started to change, it helps to know exactly which numbers and treatment decisions to discuss.
These are some of the questions patients most often ask after albumin, creatinine, or eGFR results begin to change.
Established chronic structural kidney damage is not usually fully reversible. However, albuminuria can decrease and loss of kidney function can often be slowed substantially with early treatment and careful management of glucose, blood pressure, cardiovascular risk, and kidney-protective medications.
Yes. Early kidney disease may first appear as increased UACR while creatinine and eGFR remain relatively preserved. This is one reason urine albumin testing is important.
Yes. Some people with diabetes develop reduced eGFR without substantial albuminuria. A normal UACR therefore does not completely exclude chronic kidney disease.
No. Glucose control is important, but kidney protection also depends on blood pressure, albuminuria, cardiovascular risk, smoking, weight, and the use of appropriate kidney-protective medicines when indicated.
For many people with diabetes and chronic kidney disease, current ADA guidance recommends a treatment goal below 130/80 mmHg when this can be achieved safely. The goal still needs to be individualized.
No. Kidney biopsy is not routinely required. It is mainly considered when the pattern suggests another kidney disorder, such as rapid eGFR decline, nephrotic syndrome, active urine sediment, or other atypical findings.
Yes. Some people have reduced kidney filtration without substantial albumin leakage. Doctors therefore interpret eGFR and UACR together rather than relying on either test alone.
These patient questions may help you understand how kidney results fit with other diabetes laboratory findings:
For a broader understanding of glucose control, diabetes treatment, complications, and nutrition, these guides may also be useful:
This page is for diabetes and kidney-health education and does not replace personal medical advice, diagnosis, or treatment. Kidney treatment depends on your eGFR, UACR, potassium, blood pressure, glucose control, cardiovascular health, medications, pregnancy status, and other individual factors.
Seek prompt medical assessment for rapidly worsening swelling, severe shortness of breath, confusion, persistent vomiting, markedly reduced urine output, severe weakness, severe hypoglycemia, or rapidly worsening kidney-test results.
Do not start, stop, or adjust diabetes, blood-pressure, or kidney medications based only on information from this page.
The medical information on this page is based primarily on current diabetes and chronic kidney disease guidance.